Treatment of chronic bacterial prostatitis with ciprofloxacin. 1987

T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
Department of Urology, General Hospital De Tjongerschans, Heereveen, The Netherlands.

Thirty two patients with proven chronic bacterial prostatitis were treated with ciprofloxacin 500 mg twice daily orally for four weeks. The causative organisms, cultured from prostatic fluid were Enterobacteriaceae (19 patients), enterococci (9), staphylococci (4), streptococci (3), non-fermentative Gram-negative rods (2) and anaerobic bacteria (9). Nineteen patients had pure cultures, 13 mixed cultures. The susceptibility of all organisms to ciprofloxacin, sulfamethoxazole, trimethoprim and doxycyclin was determined by agar dilution. The effect of therapy was measured by clinical parameters and by repeated cultures of prostatic fluid during and after therapy up to six months. Clinical cure (at one month after therapy) was obtained in 22 patients, improvement in seven; two patients did not respond, one patient had to stop during therapy because of severe nausea. No other side effects were noted. Ciprofloxacin may be a useful alternative drug in the treatment of prostatitis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011472 Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment. Acute Bacterial Prostatitis,Asymptomatic Inflammatory Prostatitis,Chronic Bacterial Prostatitis,Chronic Prostatitis with Chronic Pelvic Pain Syndrome,Acute Bacterial Prostatitides,Asymptomatic Inflammatory Prostatitides,Bacterial Prostatitides, Acute,Bacterial Prostatitides, Chronic,Bacterial Prostatitis, Acute,Bacterial Prostatitis, Chronic,Chronic Bacterial Prostatitides,Inflammatory Prostatitis, Asymptomatic,Prostatitides,Prostatitides, Chronic Bacterial
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004756 Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE. Enterobacterial Infections,Cronobacter Infections,Infections, Enterobacteriaceae,Infections, Enterobacterial,Cronobacter Infection,Enterobacteriaceae Infection,Enterobacterial Infection,Infection, Cronobacter,Infection, Enterobacteriaceae,Infection, Enterobacterial,Infections, Cronobacter
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
January 1990, Urology,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
January 1995, Urologiia i nefrologiia,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
January 1991, Infection,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
July 2002, International journal of antimicrobial agents,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
June 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
January 1999, Drugs,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
July 2005, The Journal of urology,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
April 1987, The American journal of medicine,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
June 2006, The Journal of urology,
T N Langemeyer, and W H Ferwerda, and J A Hoogkamp-Korstanje, and E J de Leur, and H van Oort, and J J Schipper, and T van der Wal
September 2003, Asian journal of andrology,
Copied contents to your clipboard!